Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3218931
Max Phase: Preclinical
Molecular Formula: C16H13ClN2O
Molecular Weight: 284.75
Molecule Type: Small molecule
Associated Items:
ID: ALA3218931
Max Phase: Preclinical
Molecular Formula: C16H13ClN2O
Molecular Weight: 284.75
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccc(Cc2cn3cc(Cl)ccc3nc2=O)cc1
Standard InChI: InChI=1S/C16H13ClN2O/c1-11-2-4-12(5-3-11)8-13-9-19-10-14(17)6-7-15(19)18-16(13)20/h2-7,9-10H,8H2,1H3
Standard InChI Key: UJCJRSKQFIKJMJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 284.75 | Molecular Weight (Monoisotopic): 284.0716 | AlogP: 3.25 | #Rotatable Bonds: 2 |
Polar Surface Area: 34.37 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.23 | CX LogD: 3.23 |
Aromatic Rings: 3 | Heavy Atoms: 20 | QED Weighted: 0.72 | Np Likeness Score: -1.51 |
1. Rapolu S, Alla M, Ganji RJ, Saddanapu V, Kishor C, Bommena VR, Addlagatta A. (2013) Synthesis, cytotoxicity and hDHFR inhibition studies of 2H-pyrido[1,2-a]pyrimidin-2-ones, 4 (5): [10.1039/C3MD00013C] |
Source(1):